References
- Ursič Vrščaj M, Rakar S, Možina A, Kobal B, Takač I, Deisinger I, et al. [Guidelines for management of women with cervical precancerous lesions]. [Slovenian]. In: Ursic-Vrscaj M, editor. Ljubljana: Institute of Oncology Ljubljana; 2011.
- Hybrid Capture 2 (hc2) High Risk HPV DNA test kit [package insert]. Gaithersburg, MD: Digene; 2004.
- Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, et al. Results of human papillomavirus DNA testing with the Hybrid Capture 2 assay are reproducible. J Clin Microbiol 2002; 40: 1088-90. doi: 10.1158/1055-9965.EPI-07-2904
- Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL; ALTS Group. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122: 238-45. doi: 10.1158/1055-9965.EPI-07-2904
- Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol 2005; 124: 716-21. doi: 10.1309/84E5WHJQHK83BGQD
- Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods 2006; 134: 252-6. doi: 10.1016/j. jviromet.2005.12.004
- Origoni M, Carminati G, Sideri M, Clementi M, Rolla S, Candiani M. “Low-grade positivity” of HPV viral load after atypical squamous cells of undetermined significance (ASC-US) cytology identifies women at low-risk for cervical intraepithelial neoplasia grade 2 and 3. Eur J Gynaecol Oncol 2012; 33: 261-4. PMID: 22873095
- de Cremoux P, Coste J, Sastre-Garau X, Thioux M, Bouillac C, Labbe S, et al. Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. Am J Clin Pathol 2003; 120: 492-9. doi: 10.1309/XFUC-PP6M-5XUA-94B8
- Muldrew KL, Beqaj SH, Han J, Lum SH, Clinard V, Schultenover SJ, et al. Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a “retest zone”. Am J Clin Pathol 2007; 127: 97-102. doi: 10.1309/4WCPTUV506HLP06P
- Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. J Clin Virol 2013; 58: 161-7. doi: 10.1016/j.jcv.2013.06.041
- Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Diagn Mol Pathol 2007; 16: 125-9. doi: 10.1097/ PDM.0b013e31805c99ae
- Knoepp SM, Kuebler DL, Wilbur DC. Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic/ histologic review of 367 cases. Cancer Cytopathol 2010; 118: 209-17. doi: 10.1002/cncy.20093
- LaMere BJ, Castle PE, Fetterman B, Poitras N, Stanley M, Shieh J, et al. A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting. J Virol Methods 2013; 189: 77-9. doi: 10.1016/j.jviromet.2013.01.011
- Elkins CT, de Vries CE, Stephens J, Suarez AA. Hybrid capture 2 test results after an initial equivocal RLU/CO value are dependent on age. Am J Clin Pathol 2013; 139: 605-10. doi: 10.1309/AJCPARHTB40DTVFV
- Ramirez-Hidalgo A, Musset-Biarnes M, Vilamala-Muns M, Laso-Perez E, Serrano-Munne L, Alameda-Quitllet F. Hybrid capture 2 high-risk human papillomavirus test: should “grey zone” results justify repeating the test? Anal Quant Cytopathol Histpathol 2013; 35: 152-6. PMID: 24344502
- de Vries CE, Shen R, Stephens J, Suarez AA. Equivocal and weakly positive hybrid capture 2 test in women aged 50 and older. Diagn Cytopathol 2012; 40: 708-12. doi: 10.1002/dc.21710
- Ivanus U, Jerman T, Fokter AR, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol 2018; 52: 399-412. doi: 10.2478/ raon-2018-0036
- Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. 4th edition. Lyon: International Agency for Research on Cancer; 2014.
- R Core Team. The R Project for Statistical Computing R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2019. [cited 2019 May 15]. Available at: http://www.R-project.org/
- Kotaniemi-Talonen L, Malila N, Nieminen P, Anttila A, Tarkkanen J, Laurila P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008; 123: 2902-6. doi: 10.1002/ijc.23839.
- Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55. doi: 10.1016/ S1470-2045(06)70731-8
- Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74. doi: 10.1093/jnci/djj209
- Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501. doi: 10.1093/jnci/djn065
- Sargent A, Bailey A, Turner A, Almonte M, Gilham C, Baysson H, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010; 48: 554-8. doi: 10.1128/JCM.00896-09
- Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616-23. doi: 10.1054/bjoc.2001.1845
- Rijkaart DC, Coupe VM, van Kemenade FJ, Heideman DA, Hesselink AT, Verweij W, et al. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer 2010; 103: 939-46. doi: 10.1038/sj.bjc.6605869
- Rebolj M, Bonde J, Njor SH, Lynge E. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ 2011; 23: 342. doi: 10.1136/bmj.d2757